TY - JOUR
T1 - Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size
AU - Lewis, S.
AU - Barry, A.
AU - Hawkins, M. A.
N1 - Funding Information:
M.A. Hawkins reports financial support by University College London.
Funding Information:
M.A. Hawkins is supported by funding from the NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust .
Publisher Copyright:
© 2022 The Royal College of Radiologists
PY - 2022/5
Y1 - 2022/5
N2 - The use of stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) has increased over the years. Several prospective studies have demonstrated its safety and efficacy, and randomised trials are underway. The advancement in technology has enabled the transition from three-dimensional conformal radiotherapy to highly focused SBRT. Liver damage is the primary limiting toxicity with radiation, with the incidence of grade 3 varying from 0 to 30%. The reported radiotherapy fractionation schedule for HCC, and in practice use, ranges from one to 10 fractions, based on clinician preference and technology available, tumour location and tumour size. This review summarises the safety and efficacy of various SBRT fractionation schedules for HCC.
AB - The use of stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) has increased over the years. Several prospective studies have demonstrated its safety and efficacy, and randomised trials are underway. The advancement in technology has enabled the transition from three-dimensional conformal radiotherapy to highly focused SBRT. Liver damage is the primary limiting toxicity with radiation, with the incidence of grade 3 varying from 0 to 30%. The reported radiotherapy fractionation schedule for HCC, and in practice use, ranges from one to 10 fractions, based on clinician preference and technology available, tumour location and tumour size. This review summarises the safety and efficacy of various SBRT fractionation schedules for HCC.
UR - http://www.scopus.com/inward/record.url?scp=85126532536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126532536&partnerID=8YFLogxK
U2 - 10.1016/j.clon.2022.02.021
DO - 10.1016/j.clon.2022.02.021
M3 - Article
C2 - 35314091
AN - SCOPUS:85126532536
SN - 0936-6555
VL - 34
SP - e195-e209
JO - Clinical Oncology
JF - Clinical Oncology
IS - 5
ER -